Edmund Lim, father of Branden, a young boy living with SMA Type 1, who reminds us all that science and equity, together, can change the world.
Diagnosis: A Family’s Resilience
When Branden was diagnosed with severe Type 1 spinal muscular atrophy (SMA) at the age of one, our family faced unimaginable challenges. In Malaysia, where healthcare resources for rare diseases are limited, SMA initially felt insurmountable. Breakthrough treatments like Evrysdi (risdiplam), approved in the U.S., were financially out of reach. Private insurers deemed genetic conditions “uninsurable,” leaving us feeling isolated and overwhelmed.
Yet amidst this uncertainty, hope emerged, through collective effort and compassion.
A Partnership for Progress
In 2020, Branden was welcomed into a compassionate access program for Evrysdi, made possible through the partnership of Roche, Malaysia’s Ministry of Health (MoH), and Sunway Medical Centre. We are profoundly grateful for this lifeline.
The daily oral medication has been transformative, stabilizing his breathing, reigniting his joy, and allowing him to return to one of his greatest loves: creating art. His artwork, showcased at www.brandenlim.com, is a testament to the strength that can arise from both medical progress and personal spirit. As his doctors have affirmed, Branden’s progress reflects the clear efficacy of such treatments.
Stability and the Quest for Sustainability
While Evrysdi has brought Branden much-needed stability, the program’s need for periodic renewal reminds us that compassion alone cannot replace sustainable healthcare policy. We recognize the complexity of maintaining such programs and commend both Roche and the MoH for their commitment.
Still, like many families, we dream of a future where access to life-saving treatments is not dependent on temporary arrangements. Branden’s resilience, his art, and his dreams of becoming a YouTuber, remind us of the importance of long-term, secure access.
Balancing Gratitude and Advocacy
Our gratitude for Evrysdi is deep and unwavering. But it also prompts a larger question: how can countries like Malaysia, with its ethos of MADANI, work with global partners to ensure equitable access for all?
While we recognize that production costs and pricing structures are complex, we believe that open dialogue between governments, pharmaceutical leaders, and civil society can foster creative, inclusive solutions. Countries like China and Singapore offer instructive models, proof that progress is possible when shared goals and bold action come together.
A Vision for Inclusive Healthcare
As Branden turns 15, his journey is one of resilience, but also of remarkable potential. Malaysia’s recent approval of three treatments for spinal muscular atrophy is a hopeful milestone. However, challenges remain, especially around equitable pricing and sustainable access.
This is a respectful appeal to all stakeholders: explore new models that align innovation with accessibility, where corporate excellence meets public health. This is not a critique, it is a collective call to action. Let us ensure that no child is left behind. For Branden. For every family navigating SMA and other rare diseases.
Looking Ahead with Hope
Branden’s journey shows what is possible when compassion and collaboration intersect. In the next part of this letter, I will explore global initiatives that offer pathways Malaysia might adapt, not to compare, but to learn. Together, we can foster a future where life-saving treatments are not privileges, but rights.
For more information, visit SMACARE
